Search...
Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Tradingâ What's Going On?
I'm PortAI, I can summarize articles.
Praxis Precision Medicines' stock surged 24.81% in pre-market trading after positive results from its EMBOLD study on relutrigine for SCN2A and SCN8A DEEs. The FDA will review the data soon, influencing the timing of the NDA filing. The company also completed a pre-NDA meeting for ulixacaltamide, an essential tremor treatment. PRAX stock has risen 349.53% over six months, with a market cap of $4.75 billion, showing strong momentum.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments